T1DM Immunotherapy Using Polyclonal Tregs + IL-2 (TILT)
Diabetes Mellitus - Type 1 | Diseases of the Endocrine System
What is the purpose of this trial?
The purpose of this study is to assess the safety of Tregs + IL-2 and survival of Tregs in patients with recent onset T1DM who receive infusions of autologous Tregs + IL-2.
- Ages18 - 45 years
- Trial withUniversity of California, San Francisco
- Start Date05/24/2017
- End Date07/30/2021
- Last Updated02/22/2018
- Study HIC#1607018090